

PRIVATE FUNDING OPPORTUNITIES: JUN 30, 2017

Please contact Corporate & Foundation Relations in the Office of Development at <u>devcfr@mgh.harvard.edu</u> if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than <u>15% in indirect costs (IDC)</u> will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. <u>Training fellowships</u> from foundations, public charity, and non-profit organizations <u>are excluded</u> from this minimum IDC requirement.

1. ALS Research Grants, Judith & Jean Pape Adams Charitable Foundation

The Foundation is interested in supporting research that is aimed at discovering the causes of and finding a cure for Amyotrophic Lateral Sclerosis (ALS). The Foundation funds research that is innovative and aggressive. The Foundation encourages partnerships and collaborative efforts in proposing initiatives to fill gaps not currently being investigated and that involve novel approaches. The research must be of high scientific merit.

Award Amount: Unspecified amount for 1 year Indirect Costs: 10% Proposal Deadline: Aug 4, 2017 Website: <u>http://adamsfoundation.org/als-research-grants/guidelines-and-procedures/</u>

2. Nurse Researcher Grants: Discovery Grant, Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

The Foundation's Nursing Grant Program is designed to encourage nursing research at various levels of practice. The Discovery Grant aims to support independent and experienced nurse researchers and must include plans to disseminate and share findings to improve nursing care for children with cancer.

These applications are to investigate topics and issues related to the quality of nursing care and the quality of life for children with cancer. Awards may not be used to supplement other support in a large project. Preliminary data are not required but the application must demonstrate feasibility to conduct proposed study.



Do you want to learn more about identifying external funding opportunities? See <u>ECOR's website</u> for information on the funding opps database, **COS Pivot** or contact Amy Robb <<u>arobb@mgh.harvard.edu</u>> to schedule an individual consultation or group training session. Award Amount: \$100,000 paid over 2 years Indirect Costs: None Application Deadline: Aug 21, 2017 Website: <u>https://www.alexslemonade.org/grants/program-areas/guality-life-and-care</u>

3. Early-Career Scientific Research Grants Program (NBF Scientific Research Grants

Program), American Association of Blood Banks (AABB)/National Blood Foundation (NBF) Since its inception, the NBF has awarded over \$9 million to early-career investigators through its Scientific Research Grants Program. NBF awards grants for investigator-initiated original research in all aspects of blood banking, transfusion medicine, cellular therapies and patient blood management. Many NBF early-career grant recipients have become leaders in the field.

Research content areas eligible for the grant program include the following: Immunology:

- Alloimmunization, immune modulation, and tolerance
- Animal models for the study of graft-vs-host disease
- Biology of autoimmune hemolytic anemia

Hematology:

- Autologous and allogeneic stem cell transplants
- Detection of residual disease following stem cell transplants
- Effects of growth factors in vitro and in vivo
- Biochemistry of coagulation factors

Immunohematology:

- Blood group serology
- Biochemistry of red cell antigens
- Molecular genetics of the blood groups

Infectious Diseases:

- Studies on Lyme disease, West Nile Virus, SARS and babesiosis and other emerging diseases
- Effect of allogeneic transfusion in HIV-infected and immunocompromised patients
- Improved detection of transfusion transmitted diseases

Cellular Therapies:

- Cell separation, cell culture or expansion studies for cell therapy applications
- Development of novel cell therapies or assays to measure cell viability or function
- Pilot studies in regenerative medicine
- Studies on mechanisms or roles of cells in stem cell transplantation
- Studies on cytokines or growth factors involved in stem cell differentiation

Patient Blood Management:

- Treatment of pre-admission anemia and bleeding tendencies
- Intraoperative/postoperative blood recovery
- Surgical hemostasis
- Appropriate indications for transfusion
- Changing physician behaviors
- Blood utilization review

Grants applications are evaluated on the basis of their scientific merit, relevance to and impact on transfusion medicine, focus and appropriateness to the scope of funding, and likelihood of yielding meaningful data.

Applications for research into innovative and new projects are a priority.

No particular project can be funded more than once.

An application for the same project may be submitted up to three times if not already NBF funded.

Awards will not be made to increase the funding available for currently funded research projects. NBF grants are intended to provide "seed" funding that allows the principal investigator to enhance preliminary data. This data may then be useful in applying for larger grants.

Award Amount: \$75,000 paid over 1-2 years Indirect Costs: None Application Deadline: Dec 1, 2017 Website: <u>http://www.aabb.org/research/nbf/Pages/grantapplication.aspx</u>

4. R. Robert and Sally Funderburg Research Award in Gastric Cancer, American Gastroenterological Association (AGA)/AGA Research Foundation

This grant is awarded to an established investigator working on novel approaches in gastric cancer research, including the fields of gastric mucosal cell biology; regeneration and regulation of cell growth (not as they relate to peptic ulcer disease or repair); inflammation (including Helicobacter pylori) as precancerous lesions; genetics of gastric carcinoma; oncogenes in gastric epithelial malignancies; epidemiology of gastric cancer; etiology of gastric epithelial malignancies; or clinical research in the diagnosis or treatment of gastric carcinoma. The overall objective of this award is to support an established investigator in the field of gastric biology whose research will enhance the fundamental understanding of gastric cancer pathobiology in order to ultimately prevent or develop a cure for the disease. Applications that do not denote a gastric biology focus and are not responsive to this announcement will not be submitted for review.

The recipient will be selected based on novelty, feasibility and significance of the proposal. Preference will be given to novel approaches.

Award Amount: \$100,000 paid over 2 years Indirect Costs: None Application Deadline: Aug 4, 2017 Website: <u>http://www.gastro.org/research-funding</u>

5. Uncovering New Patterns Grants (Uncovering New Patterns in Cardiovascular Disease and Stroke Grant), American Heart Association (AHA)/Institute for Precision Cardiovascular Medicine New

The purpose of this award is to uncover new patterns and make new discoveries within and across existing data sets using cloud computing. Specifically, this funding opportunity seeks to:

- test methods for data harmonization across different datasets to allow critical questions to be asked in larger populations regarding biomarkers, genetic variants, or other variables using cloud computing;
- test new methods for uncovering patterns within and across datasets using cloud computing;
- test new hypotheses for old yet unsolved problems within and across existing datasets using cloud computing;
- identify new biomarkers, genetic variants, behavioral influences, and environmental changes within and across existing datasets using cloud computing.

Applicants are highly encouraged to work within the AHA Precision Medicine Platform and Marketplace of tools (http://precision.heart.org), and provide a detailed paragraph in the research plan as to how the work proposed will serve the greater community.

Applicants are to provide proposals that adhere to the above broad objectives while specifically addressing the outlined goals.

Award Amount: \$150,000 for 1 year Indirect Costs: 10% Application Deadline: Aug 24, 2017 Website: http://professional.heart.org/professional/ResearchPrograms/InstituteforPrecisionCardiovascula rMedicine/UCM 461668 Information-on-the-Institute-for-Precision-Cardiovascular-Medicine.jsp

6. Uncovering New Patterns Fellowships (Uncovering New Patterns Fellowship in Cardiovascular Disease and Stroke), American Heart Association (AHA)/Institute for Precision Cardiovascular Medicine New

The purpose of this fellowship is to train a generation of postdoctoral fellows in the scientific area of cardiovascular diseases and stroke and cloud computing. Specifically, this funding opportunity seeks to:

- test methods for data harmonization across different datasets to allow critical questions to be asked in larger populations regarding biomarkers, genetic variants, or other variables in cloud computing;
- test new methods for uncovering patterns within and across datasets in cloud computing;
- test new hypotheses for old yet unsolved problems within and across existing datasets in cloud computing;
- identify new biomarkers, genetic variants, behavioral influences, and environmental changes within and across existing datasets in cloud computing.

Applicants are highly encouraged to work within the AHA Precision Medicine Platform and Marketplace of tools (http://precision.heart.org), and provide a detailed paragraph in the research plan as to how the work proposed will serve the greater community.

Award Amount: \$150,000 paid over 2 years Indirect Costs: 10% Application Deadline: Aug 24, 2017 Website: <u>http://professional.heart.org/professional/ResearchPrograms/InstituteforPrecisionCardiovascula</u> <u>rMedicine/UCM 461668 Information-on-the-Institute-for-Precision-Cardiovascular-Medicine.jsp</u>

7. Grants, American Society for Parenteral and Enteral Nutrition (ASPEN)/ASPEN Rhoads Research Foundation

The Foundation funds exceptional scientific research projects submitted by early-career investigators of clinical nutrition and metabolic support in alignment with the priorities outlines in the ASPEN Research Agenda.

Future research should include both basic science-oriented investigations aimed at improving our understanding of the science of nutrient regulation in different disease states, as well as clinical and translational research to determine how the practice of nutrition support can continue to be refined and individualized to optimize clinical outcomes.

The smaller grants may be most useful to support data collection and analysis for small projects including those that are part of a Masters, PharmD, or PhD program, or to support preliminary data accrual for a new line of investigation.

Award Amount: Up to \$50,000 paid over 2 years Indirect Costs: None Application Deadline: Aug 23, 2017 Website: https://www.nutritioncare.org/Research/ARRF/ASPEN Rhoads Research Foundation Grants/

8. Research Grant Program, Amyloidosis Foundation

For over a decade, the Amyloidosis Foundation grant program has supported outstanding research in all forms of systemic amyloidosis. Through the research program the foundation encourages, promote and invest in the medical study and exploration of the amyloidosis diseases. The Amyloidosis Foundation grant program supports basic biomedical and clinical research on systemic amyloidosis.

Award Amount: \$50,000 Indirect Costs: 15% Application Deadline: Sep 15, 2017 Website: <u>http://www.amyloidosis.org/research/#grant-programs</u>

9. NARSAD Distinguished Investigator Grants, Brain & Behavior Research Foundation (BBRF)

The Foundation is the largest non-governmental, donor-supported organization that distributes funds for brain and behavior disorder research. This grant program supports basic and/or clinical investigators who are established scientists. Research must be relevant to schizophrenia, mood disorders or other serious mental illnesses including research with anxiety, bipolar disorders, personality disorders or early and or late onset of severe brain and behavior disorders.

The program is designed to stimulate the development of key personnel and resources, to facilitate the rapid initiation of research in innovative areas, and to enable investigators to create unique scientific opportunities. The following are illustrative examples, but are not meant to identify priority areas, as innovative research in other areas is encouraged if the work is relevant to the Foundation's mission. Investigators applying for support are encouraged to define any area of scientific promise.

- Unique Patient Resources: Patient populations with unusual characteristics may prove informative if available as a resource to investigators. An example would be substantial numbers of representative patients who are lifetime drug-naïve or a post mortem collection where imaging and neurobehavioral data was collected during life.
- Unique Conceptual Opportunities: There is an explosion of information relevant to the development of the central nervous system and the various influences on this development. Much of this work takes place independent of disease interest. NARSAD Grant funding could facilitate a synthesis of experimental neuroscience and clinical

concepts in developing novel and testable theories of schizophrenia and depression. The intent here would be the heuristic and generative influence of new etiologically relevant concepts.

• Genomic/Proteomic: Rapid advances in gene and protein identification present new opportunities for discovery of vulnerability genes and disease-related proteins. Transgenic animal models of severe mental illness based on genetic information may provide new approaches to the neurobiology of schizophrenia and depression.

These interests are listed only as examples. The Foundation seeks any novel and meritorious proposal relevant to the basic and clinical science of serious mental illness such as schizophrenia and affective disorders.

Award Amount: \$100,000 for 1 year Indirect Costs: 8% Application Deadline: Jul 19, 2017 Website: <u>https://www.bbrfoundation.org/grants-prizes/narsad-distinguished-investigator-grants</u>

10. Research Project Grants, Cerebral Palsy Alliance/Research Foundation of Cerebral Palsy Alliance

The Research Foundation has a strong on-going commitment to funding high quality research in cerebral palsy. The project should addresses the Research Foundation's priorities:

- Aetiology, causal pathways
- Prevention
- Early identification, early intervention
- Novel interventions, novel treatments
- Cure.

Projects that address the causes, prevention, early interventions and cure of cerebral palsy will be rated more favourably when reviewing the merit of applications.

Award Amount: \$180,000 USD Indirect Costs: Unspecified Application Deadline: Aug 31, 2017 Website: <u>https://research.cerebralpalsy.org.au/funding/how-to-apply/</u>

11. LeRoy Matthews Physician-Scientist Award, Cystic Fibrosis Foundation (CFF)

The award was established by CFF to honor and in memory of Dr. LeRoy Matthews' dedication and commitment to CF research and care. The award encourages outstanding newly trained pediatricians and internists to enhance clinical proficiency in CF-related sub specialties and to develop the necessary research capabilities to become independent biomedical investigators. The award provides individuals who are either enrolled in or are about to enroll in sub specialty training with the opportunity to undertake up to six (6) years of support for their clinical training, research training, and the initiation of their research career. It is anticipated that the award will provide the opportunity for clinicians to obtain sub specialty training, to develop into independent investigators, and to initiate a research program.

The level of effort requested for Phases I and II is commensurate with acquiring board eligibility in the sub specialty and developing proficient skills in CF-related research. Phase III requires that a minimum of 75% effort be devoted to the research and research training program. The balance of effort can be devoted to other clinical and teaching pursuits only if they are consonant with the program goals.

Proposed research must be relevant to the CFF's mission and to the health and well-being of CF patients. Applicants are encouraged, but not required, to address an emerging area of potential interest stated below. All applications are reviewed and scored not only on scientific merit but also on relevance to the CFF's mission.

Emerging areas of interest to the CF Foundation:

- 1. Development and characterization of model systems, including patient derived samples (such as nasal and intestinal cells) and induced pluripotent stem cells (iPSC) for the study of CFTR mutations other than F508del
- 2. Direct and indirect influences of CFTR modulation on the airway milieu in patients, animal models, and in vitro studies, including resident pathogens, inflammation, mucin structure (tethered and secreted), airway surface liquid (ASL), and mucociliary clearance
- 3. Novel means for restoring CFTR function
 - Gene editing/repair strategies
 - Delivery methods for gene, RNA, and protein to the lung and other affected tissues
 - Cellular targets for CFTR correction Lung progenitor cells, airway stem cell niche
 - Understand defects associated with nonsense mutations and approaches for overcoming these effects
 - Biological mechanisms involved in lung allograft dysfunction/rejection and transplant immunology
 - Effect of CFTR activity on lung inflammation, inflammatory cell function, and bacterial killing and clearance
 - Difficult to treat CF infections (i.e. NTM, MRSA, Aspergillus)
 - Approaches to understand and treat CF related GI issues and the impact of nutritional deficiencies
 - Effects of endocrine system dysfunction in CF, including Cystic Fibrosis Related Diabetes (CFRD)

Funding priority will be placed on those projects that will lead to a better understanding of disease mechanisms, pathophysiology, and prevention, and treatment strategies.

Award Amount: \$605,000

Support ranges from \$60,000 (stipend) plus \$10,000 (research and development) for year one, to \$100,000 (stipend) plus \$30,000 (research and development) for year six Indirect Costs: None Application Deadline: Sep 13, 2017 Website: <u>https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Career-Development-Awards/LeRoy-Matthews-Physician-Scientist-Award/</u>

12. Postdoc-to-Faculty Transition Awards, Cystic Fibrosis Foundation (CFF) New

The award is designed to support postdoctoral research fellows during their CF fellowship and aid in their transition to an independent research faculty position.

Awards can provide individuals up to five (5) years of combined support for their research training (maximum of 3 years, known as "Phase I") and the initiation of their independent research career (2 years, known as "Phase II"). It is anticipated that the award will provide the opportunity for awardees to hone research skills, develop into independent investigators, and initiate an independent CF research program.

Phases:

The program and individual award application is designed in two phases, as follows:

Phase I: Outline for research training to occur during the fellowship: This phase of the award is intended to provide support for up to three (3) years to develop research and professional development skills and undertake research training in an area of priority to CFF. As part of this application, applicants are only required to submit a Research Plan for Phase I. Grantees and their sponsors will be required to submit additional materials prior to the initiation of Phase II.

Phase II: Independent Research Investigation (first independent application): This phase is intended to provide support for up to two (2) years for independent research studies. This support need not occur at the institution where Phase I took place. The outline for this work should be submitted for consideration by CFF near the end of Phase I, coinciding with the first academic appointment. In addition to scientific merit, CFF will assess the institution's commitment to the research career development of the recipient in his/her first academic appointment. At least 75% of the candidate's time must be devoted to CF-related research during Phase II.

The award will not be made for Phase II independently. Grantees who transition to an independent faculty position before the end of their third year of training support (at an institution other than where they received their Phase I training) may add a maximum of one

(1) additional year onto Phase II of the award. Transition early into Phase II of the award must be approved by the CFF Program Director.

The candidate's progress and career goals will be subject to annual evaluation by CFF throughout Phase I. Transition to Phase II will be subject to an additional review by CFF, with the scientific merit of the proposed research project evaluated, as well as the institutional commitment to the career development of the candidate.

It is desirable for individuals to complete both phases of the program without interruption. It may be permissible, however, to interrupt the award and delay the start of Phase II, such as to receive additional training, or if a tenure-track faculty position is not obtained. In the event such a contingency arises, the grantee and the Sponsor must notify CFF of the interruption and receive approval to assure that funds will be available to resume the award so that the candidate may complete the program.

The majority of morbidity and mortality associated with CF today is due to lung disease. In CF, innate defenses are compromised and inhaled or aspirated pathogens are able to establish chronic infections. CF is unique in that only a small subset of pathogens have been linked to disease progression, and the infection remains, for the most part, compartmentalized. Unfortunately, the neutrophil dominant inflammatory response causes tissue destruction and compromised organ-level function. Both the host and pathogen adapt as the initial insult evolves into an indolent, chronic infection punctuated by acute exacerbations.

KalydecoTM (VX-770), the first drug to target the basic CFTR defect, demonstrated that CFTR modulating drugs improve clinical parameters such as sweat chloride, lung function, and body weight. CFF will continue to support efforts that improve our understanding of basic defects as well as mechanisms by which CFTR modulators improve patient outcomes. While CFTR biogenesis, trafficking, structure/function, airway defense, and microbial adaption to the CF lung remain relevant, CFF will prioritize funding of projects that are focused in areas of research that may lead to the development of new and innovative therapies. Investigators working in these areas are encouraged to submit an application for consideration.

Emerging areas of potential interest to the CF Foundation:

- 1. Molecular characterization of CFTR mutations other than F508del
- 2. Direct and indirect influences of CFTR modulation on the airway milieu in patients, animal models, and in vitro studies, including resident pathogens, inflammation, mucin structure (tethered and secreted), airway surface liquid (ASL), and mucociliary clearance
- 3. Novel means for restoring CFTR function
 - a. Gene editing/repair strategies
 - b. Delivery methods for gene, RNA, and protein to the lung and other affected tissues
 - c. Cellular targets for CFTR correction
 - d. Lung progenitor cells, airway stem cell niche

- 4. Mechanisms associated with mRNA stability and translational regulation, specifically related to nonsense mutations and means to overcome them
- 5. Development and characterization of model systems, including patient derived samples (such as nasal and intestinal cells) and induced pluripotent stem cells (iPSC)
- 6. Biological mechanisms involved in lung allograft dysfunction/rejection and transplant immunology
- 7. Effect of CFTR activity on lung inflammation, inflammatory cell function, and bacterial killing and clearance
- 8. Difficult to treat CF infections (i.e. NTM, MRSA, Aspergillus)

Funding priority will be placed on those projects that will lead to a better understanding of disease mechanisms, pathophysiology, and prevention, and treatment strategies.

Award Amount: Up to \$300,500 Indirect Costs: None Application Deadline: Sep 13, 2017 Website: <u>https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Training-Awards/Postdoc-to-Faculty-Transition-Awards/</u>

13. Harry Shwachman Cystic Fibrosis Clinical Investigator Award, Cystic Fibrosis Foundation (CFF)

The award provides the opportunity for promising, clinically-trained physicians with a commitment to research to develop into independent biomedical researchers who have active involvement in CF-related areas. The award helps facilitate the transition from postdoctoral training to an academic career as an independent investigator.

The award enables candidates to undertake research, tailored to the individual's interests and needs, with a sponsor(s) who is/are competent to provide appropriate research guidance and supervision. A minimum of 70% of the applicant's time must be devoted to research.

Proposed research must be relevant to the CFF's mission and to the health and well-being of CF patients. Applicants are encouraged, but not required, to address an emerging area of potential interest stated below. All applications are reviewed and scored not only on scientific merit but also on relevance to the CFF's mission.

Emerging areas of interest to the CF Foundation:

- 1. Development and characterization of model systems, including patient derived samples (such as nasal and intestinal cells) and induced pluripotent stem cells (iPSC) for the study of CFTR mutations other than F508del
- 2. Direct and indirect influences of CFTR modulation on the airway milieu in patients, animal models, and in vitro studies, including resident pathogens, inflammation, mucin

structure (tethered and secreted), airway surface liquid (ASL), and mucociliary clearance

- 3. Novel means for restoring CFTR function
 - Gene editing/repair strategies
 - Delivery methods for gene, RNA, and protein to the lung and other affected tissues
 - Cellular targets for CFTR correction Lung progenitor cells, airway stem cell niche
- 4. Understand defects associated with nonsense mutations and approaches for overcoming these effects
- 5. Biological mechanisms involved in lung allograft dysfunction/rejection and transplant immunology
- 6. Effect of CFTR activity on lung inflammation, inflammatory cell function, and bacterial killing and clearance
- 7. Difficult to treat CF infections (i.e. NTM, MRSA, Aspergillus)
- 8. Approaches to understand and treat CF related GI issues and the impact of nutritional deficiencies
- 9. Effects of endocrine system dysfunction in CF, including Cystic Fibrosis Related Diabetes (CFRD)

Funding priority will be placed on those projects that will lead to a better understanding of disease mechanisms, pathophysiology, and prevention, and treatment strategies.

Award Amount: \$390,000 paid over 3 years Indirect Costs: None Application Deadline: Sep 15, 2017 Website: <u>https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Career-Development-Awards/Harry-Shwachman-Clinical-Investigator-Award/</u>

14. Meniere's Disease Grants, Hearing Health Foundation (HHF)

Hearing Health Foundation (HHF) is requesting fundamental and clinical research proposals that will significantly advance our understanding of disease mechanisms, or diagnosis and treatment of Ménière's Disease, the inner ear and balance disorder.

Areas of interest include:

- the mechanisms of endolymphatic hydrops including mechanisms of cochlear fluid regulation;
- genetics;
- the creation of animal models;
- vertigo;
- vestibular migraines;
- the imaging of hydrops; and

• etiology, diagnosis, and treatment.

Award Amount: \$100,000 paid over 2 years Indirect Costs: 10% Application Deadline: Sep 1, 2017 Website: <u>http://hearinghealthfoundation.org/menieres-disease-grants-policy</u>

15. SWOG/Hope Foundation Impact Award, The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 4,000 cancer researchers at more than 500 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

The SWOG/Hope Foundation Impact Award is a funding program from The Hope Foundation that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources from completed SWOG trials or be directly translatable to future clinical trials in SWOG and the NCTN.

These studies may involve considerable scientific risk but may potentially lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research. It is expected that support via this mechanism will lead to subsequent extramural support from other sources, and will be a metric of success for this grant awarding program. In addition, publications citing SWOG and The Hope Foundation will be further metrics for success of the program.

Achieving SWOG's mission of changing the practice of cancer medicine in clinical trials requires innovative ideas, techniques and perspectives. SWOG and The Hope Foundation understand that novel ideas might not align with current thinking or may not yet be supported by substantial preliminary data. The Impact Award Program is intended to foster novel scientific ideas, agents, targets, and technologies that have the potential to substantially advance the practice of clinical cancer research within the Group. For example, a project may seek to identify new predictive bio-markers for prevention, supportive care or therapeutic studies, assess the feasibility of an agent device or measurement tool, identify resistance mechanisms, develop new technologies for monitoring therapeutic response, or develop and test novel methodologies to assist with the conduct of health care delivery studies.

Award Amount: \$250,000 paid over 2 years Indirect Costs: 25% Submission Deadline: Sep 1, 2017 Website: <u>https://thehopefoundation.org/research-funding/juried-programs/swog-hope-foundation-impact-award/</u>

16. Saving Lives at Birth in Low-Resource Setting, Laerdal Foundation for Acute Medicine

Support from the Foundation will be focused on practically oriented projects helping:

- Reducing infant and child mortality by 2/3 from 2010 to 2030
- Reducing maternal deaths by 2/3 from 2010 to 2030

The Board particularly welcomes applications relating to:

- Innovative approaches to more efficient education and implementation
- Collaborative initiatives, such as the Helping Babies Survive and Helping Mothers Survive and Survive & Thrive Global Development Alliances
- Projects in selected focus countries; Tanzania, Ethiopia, Malawi, Bangladesh, India, Nepal

In considering applications for projects in developing countries, the Board will be prioritizing projects that beyond a local impact have the potential to document long term practical value, and stimulate developments also in other regions/countries through publication of results in peer reviewed journals.

Award Amount: \$50,000 Indirect Costs: None Application Deadline: Oct 1, 2017 Website: <u>https://laerdalfoundation.org/about/saving-lives-at-birth/</u>

17. SCCM-Weil Research Grant, Society of Critical Care Medicine (SCCM)

This grant is awarded annually to SCCM members for research to be carried out in basic, translational or clinical research.

SCCM seeks to sponsor research efforts that will ultimately improve patient care in the intensive care unit (ICU) and after ICU discharge. Investigator-initiated research should help advance and improve our understanding of critical illness and patient care.

Interest is broad. Applications are encouraged that focus on expanding our basic knowledge of critical illness, clinical interventions to improve patient outcomes and technical aspects such as electronic surveillance systems, as well as studies exploring cultural and educational factors among ICU staff that either impede or facilitate a climate promoting best practices and error reduction. Priority will be given to projects that have broad relevance and/or community engagement. For example, single-center projects should specifically address the potential to generalize their findings to other critical care settings.

Each application should fit into one of the following key research priority areas:

- General Principles: Developing and applying rigorous methodology to basic, clinical, health services and translational research experimental design and to the evaluation of evidence. Developing better models of critical illness and incorporating novel approaches in bench research to account for variations in patients, care strategies and therapeutic interventions. Integrating new areas of research, scientific disciplines and technology into the study of critical illness.
- Basic Science/Cellular Research: Investigating the role of the host response in initiation, transition and resolution of critical illnesses. Defining the normal microbiome and investigating its role and transitions in critical illnesses. Integrating research in the biology of tissue repair with investigation into mechanisms that underlie critical illnesses.
- Translational Research: Integration of studies of critical care mechanisms and interventions and application of rigorous, standardized methodology to study design. Investigating the reasons for treatment effects and management of disease progression.
- Clinical Research: Developing methods for the rapid, early recognition of acute, severe disease in patients at high risk for imminent deterioration. Developing minimally invasive, biocompatible organ support, focusing on therapeutic manipulation of the neuroinflammatory state and exploring new approaches that enhance patient comfort while reducing the need to manipulate consciousness. Identifying the best process and outcome measurements for critical illness research and palliative and end-of-life care.
- Health Service and Delivery Research: Identifying variables that affect outcomes and developing meaningful and reproducible performance metrics and improvement processes, including those related to quality improvement and patient safety. Measuring the effectiveness of interventions to measure and treat prevalent and/or distressing patient and family symptoms. Identifying strategies to improve communication and coordination of care delivery and determining which tools, processes and programs (e.g., checklists and multidisciplinary rounds) most effectively promote knowledge transfer and implementation. Examining factors related to establishing a positive learning environment (e.g., technological advances, minimizing cognitive overload and avoidance of burnout), strategies for preventing errors and facilitating error reporting, and assessing the effects on patient outcomes.
- Education Research: Incorporating cognitive psychology, systems engineering, social science and simulations into critical care education and training. Refining team-based learning, including examining differences between high- and low-performing units and determining in which scenarios team-based learning has the greatest value.
- Patients and Families: Survivorship and Recovery: Investigator-initiated research to help advance and improve our understanding of survivorship from critical illness, as well as support and improve the experiences of survivors and their families. Clinical interventions to improve patient experiences or outcomes, identification of modifiable mechanisms or testing of innovations that promote recovery or explorations of cultural and educational factors among survivors to facilitate networks and improve support.

Award Amount: \$50,000 Indirect Costs: 10% Application Deadline: Aug 1, 2017 Website: http://www.sccm.org/Research/grants/Pages/SCCM-Research-Grants.aspx

18. Victoria S. Levin Grant for Early Career Success in Young Children's Mental Health Research, Society for Research in Child Development (SRCD)

The grant's aim is to foster early career success in achieving funding for research that is informed by developmental science to address concerns affecting the early foundations of children's mental health. The Grant will add measurably to Vicki's dream of a society in which all children are protected from disabling mental health problems by getting the healthiest start in life. Vicki believed strongly in the NIH's critical role in creating a scientific basis for achieving this goal and in the need to attract the best and brightest new scientists. Therefore, the VSL Grant is designed to increase the likelihood that promising early career scientists succeed in securing NIH funding.

The Grant serves the promising pre-tenured, junior investigator by:

- Supporting release time from duties during which time the awardee writes and submits an application in the area of early childhood mental health to the NIH. This support compensates the awardee's unit/department for the work from which the awardee is released. Having adequate time to develop and submit a grant application is essential for early career success.
- Providing travel funds for a trip to NIH to meet program staff. This support helps the awardee develop meaningful contacts with NIH program staff who can guide the application preparation and revision (funding usually requires two application submissions).
- Providing a pre-review of the application. The opportunity to hire a distinguished scientist to review the application in advance of submission to NIH heightens the chances of early success. In addition to providing a critique, the reviewer can also advise the new scientist, which NIH review panels cannot do.

Award Amount: Unspecified Indirect Costs: Unspecified Application Deadline: Sep 1, 2017 Website: <u>http://www.srcd.org/advancing-field/srcd-awards-research-grants/victoria-s-levin-grant</u>

19. Special Initiatives: The Social, Economic and Political Effects of the Affordable Care Act, Russell Sage Foundation (RSF)

The Affordable Care Act (ACA) of 2010 represents the most significant reform of the U.S. health care system in decades. It was enacted with the goals of increasing access to health insurance, enhancing the quality of care and moderating the growth in costs. The new law is likely to have far reaching effects, beyond the way health insurance markets operate and beyond its impact on population health outcomes. It is those other social, economic and political effects of the ACA that we seek to understand.

Examples of the kinds of topics and questions that are of interest include, but are not limited to, the following:

- Financial Security and Family Economic Well-Being
- Labor Market Outcomes
- Public Program Participation
- Family and Children's Outcomes
- Immigrant Outcomes
- Effects on Politics, Political Culture, and Public Policy
- Outcomes for Underserved Groups

Funding is available for secondary analysis of data or for original data collection. Projects that propose novel uses of existing data are welcome, as are projects that propose to analyze newly available or underutilized data. The sponsor will not fund research on the effects of the ACA on health care delivery or health outcomes (e.g., barriers to implementation, changes in the quality of care and health status, or trends in enrollment and affordability).

The Foundation encourages methodological variety and inter-disciplinary collaboration.

Award Amount: \$150,000 for up to 2 years Indirect Costs: 15% LOI Deadline: Aug 21, 2017 Website: <u>http://www.russellsage.org/research/funding/affordable-care-act</u>